Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
The DOI matches its Crossref record; 299 of the 300 references it cites were found in a registry or an index.
Abstract
Abbreviations: A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ABCD = adiposity-based chronic disease; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACE = American College of Endocrinology; ACEI = angiotensin-converting enzyme inhibitor; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CGM = continuous glucose monitoring; CHD = coronary heart disease; CKD = chronic kidney disease; DKA = diabetic ketoacidosis; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density-lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; LDL-C = low-density-lipoprotein cholesterol; LDL-P = low-density-lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium-glucose cotransporter 2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epidemiologic evidence shows a continuous relationship between A1C and CVD and all-cause mortality.72”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [72]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cited by
Items 401–500 of 610
The diabetic patient between sustainability and effectiveness of new treatments
Ferrara, F., Zovi, A., Langella, R., Nava, E., & Trama, U. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01296-0 · Cited by 2
“In 2020, a Consensus Statement [31] was published for the integrated treatment of type 2 diabetes from the American societies of endocrinology (American Association of Clinical Endocrinologists and American College of Endocrinology).”
BackgroundMODERN APPROACH TO THE PREVENTION OF TYPE 2 DIABETES IN THE ELDERLY
Владиславовна, К. О., Bulgakova, S. V., Долгих, Ю. А., Sharonova, L. A., Тренева, Е. В., & Курмаев, Д. П. (2023) · Успехи геронтологии · doi:10.34922/ae.2023.36.4.013 · Cited by 2
Changing Fields-Diabetes Medications Invading the Cardiovascular Space
Breite, L. D., Steck, M., Cutshall, B. T., Shah, S. P., & Cave, B. E. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100736 · Cited by 3
SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Stanton, R. C. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.003 · Cited by 2
Garvey, W. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00018-8 · Cited by 2
Self-citationSingh, N., Dove, E., & Bhatt, D. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00019-4 · Cited by 4
Preoperative Patient Evaluation
Villasenor, M., & Selzer, A. R. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.08.004 · Cited by 2
Rosenstock, J., Cariou, B., Eliasson, J., Frappin, G., Kaltoft, M. S., Montanya, E., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15339 · Cited by 2
Pitts, M. A., Griggs, R. H., Hall, M., Tankersley, M., & Johnson, J. L. (2023) · Diabetes Spectrum · doi:10.2337/ds23-0052 · Cited by 2
Pandya, N., & Patel, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_38 · Cited by 2
Lertwanichwattana, T., Suwannahitatorn, P., Mungthin, M., & Rangsin, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298010 · Cited by 3
“Assessing glycemic control using HbA1c, according to ADA 2020, recommends evaluating the level quarterly per year among patients whose therapy has changed or who are not meeting glycemic goals [10].”
BackgroundMethodInfluentialKumthekar, P., Upadhyay, M., Tamma, R. R., Kranti, V., Bhattacharya, R., Sharma, P. K., Barge, V. B., Revankar, S. Y., & Ghatge, S. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_169_24 · Cited by 2
Eficacia y seguridad de liraglutida para la disminución de peso en adultos: revisión sistemática
Rodríguez, D. C. H., Sánchez, D. M., & Ramírez, A. P. (2021) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.7.4.651 · Cited by 3
Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes
Solis‐Herrera, C., Cersósimo, E., & Triplitt, C. L. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0067 · Cited by 3
Comparative efficacy and safety of basal insulins: A review
Vargas‐Uricoechea, H., & Montoya, P. A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102318 · Cited by 2
Valeeva, F. V., Medvedeva, M. S., Khasanova, K. B., Turtseva, T. S., & Yilmaz, T. S. (2021) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2021-12-4-27-33 · Cited by 2
Addressing Overbasalization to Achieve Glycemic Targets
Cowart, K., Franks, R. B., Pane, O., Murphy, E., & Oldziej, K. (2022) · ADCES in Practice · doi:10.1177/2633559x211068884 · Cited by 2
“5 units/kg/d, clinicians should consider adding an injectable therapy to address postprandial hyperglycemia if the A1C remains above the desired target.(13,14) The rationale for this recommendation is based on basal insulin having a ceiling effective dose whereby fasting blood glucose reductions become proportionally…”
BackgroundCardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks
Wong, N. D. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0065 · Cited by 2
Insulinoterapia en pacientes con diabetes mellitus tipo 2. Una revisión narrativa
González-Wong, C., Fuentes-Barría, H., & Aguilera-Eguía, R. A. (2022) · Enfermería Universitaria · doi:10.22201/eneo.23958421e.2021.3.1096 · Cited by 6
Ma, Y., Zhou, Z., Li, X., Ding, K., Xiao, H., Wu, Y., Wu, T., & Chen, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1009095 · Cited by 4
An insight into the use of estetrol-drospirenone as effective oral contraceptive
Chaudhry, H., Rangra, N. K., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100072 · Cited by 2
Zagury, R., Lacativa, P. G. S., de Gregório, L. H., Rosenfeld, V. A. S., Campos, L. F., Pinheiro, R. A. C., da Costa, S. F., & Russo, L. A. T. (2022) · Nutrición Hospitalaria · doi:10.20960/nh.04204 · Cited by 3
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
Sustainability and evolution of health care regarding treatments concerning type 2 diabetes mellitus
Ferrara, F., Zovi, A., Langella, R., Cavallaro, F., Nava, E., Trama, U., & Vitiello, A. (2023) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2023.100890 · Cited by 2
Dietary Modulation of Chronic Inflammation of Diabetes: A Narrative Review
Joseph, S. (2023) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000181 · Cited by 2
Pharmacotherapy of Type 2 Diabetes Mellitus
Jha, P. K., Shukla, H., Makwana, A., & Kakkad, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002309 · Cited by 4
Fonseca, V. A., Sood, M., & Galindo, R. J. (2021) · Clinical Diabetes · doi:10.2337/cd20-0121 · Cited by 2
“Theyalsodiscussglucagon-likepeptide1 receptor agonists (GLP-1 RAs), which are the recommended first injectable therapy for the majority of people with type 2 diabetes (1,2) because of their glycemic efficacy and lack of association with weight gain and hypoglycemia.”
BackgroundCost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes
Kheloussi, S. S., Johns, A. M., Parente, V., McLay, W., & Gionfriddo, M. R. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.846 · Cited by 2
Wu, S., Zhao, Z., Liu, S., Li, M., Wang, T., Wang, S., Xu, M., Chen, Y., Dai, M., Zhang, D., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13213 · Cited by 2
Kim, H. S., Yu, J. M., Jang, H. C., Choi, E. K., Park, J. H., Shon, H. S., Chung, C. H., Park, K., Cho, J., Kim, W., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s334944 · Cited by 2
Wang, N., Zoungas, S., & Chalmers, J. P. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104160 · Cited by 3
Metabolic Surgery Needs Stronger Endorsement
Gagner, M. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05344-7 · Cited by 2
Bright, T. M. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002268 · Cited by 2
Guidelines on Antidiabetic Drugs
Fisher, M., & Drummond, R. S. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch15 · Cited by 2
It Is Time to Reconsider the Blood Pressure Targets in Patients With Type 2 Diabetes?
Verdecchia, P., Reboldi, G., & Angeli, F. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21461 · Cited by 2
An insight to the diabetic ketoacidosis and lactic acidosis among the SARS-COV2 infected individuals
Al-Sa'idy, H. A. H., Al‐Snafi, A. E., & Alyousif, B. (2022) · Magna Scientia Advanced Biology and Pharmacy · doi:10.30574/msabp.2022.6.1.0071 · Cited by 1
Tratamiento farmacológico del paciente que vive con diabetes mellitus tipo 2
Rincón, A. R., Betancur, S. S., Ramos, A. F. G., González-Arango, J., & Vargas, L. V. E. (2022) · CES Medicina · doi:10.21615/cesmedicina.6672 · Cited by 1
Grassi, B. A., Hernández, C., Boncompte, M., Henríquez, C., Marinovic, N. L., Miranda, F., Papic, K. V., & Alfaro, V. R. (2022) · Revista médica de Chile · doi:10.4067/s0034-98872022001001334 · Cited by 1
“…si bien por décadas se ha con-siderado el uso de insulina rápida como la herra-mienta más poderosa para el control de la DM2, en los años recientes su uso ha quedado relegado a última línea en guías internacionales debido a su complejidad, gran riesgo de hipoglicemia y gran ganancia de peso 7,8 .”
BackgroundCummings, P. J., Washburn, P. J., Schneider, J. A., Miosi, S. E., & Nichols, D. M. (2023) · AJPM Focus · doi:10.1016/j.focus.2023.100118 · Cited by 1
Use of Insulin in Outpatient Diabetes Management
Faradji, R. N., de la Maza, E. S., Menchaca, A. P. D.-B., & Sanromán, J. R. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_37 · Cited by 2
Guidelines-disease-specific and context blind: a case of type 2 diabetes
Violante-Cumpa, J. R., Gonzalez‐Cruz, D., Rios-Ortega, A. G., González‐González, J. G., & Rodríguez‐Gutiérrez, R. (2023) · Medicina Universitaria · doi:10.24875/rmu.23000037 · Cited by 1
Ersoy, S., & Gürfidan, R. (2024) · Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi · doi:10.22312/sdusbed.1449989 · Cited by 1
Hamid, S. A., Graetz, E., Zolfaghari, E. J., Schultz, K. S., Schneider, E. B., & Gibbs, K. E. (2025) · Perioperative Medicine · doi:10.1186/s13741-024-00483-8 · Cited by 1
“These patients can benefit from perioperative optimization in accordance with American Association of Clinical Endocrinology guidelines (Garber et al. 2020; Lee et al. 2020) and, for some, surgery may need to be delayed to optimize outcomes.”
Masroor, M., Haque, Z., Anwar, H., Hanif, F., & Farooqui, W. A. (2025) · Human Gene · doi:10.1016/j.humgen.2025.201453 · Cited by 1
Latreille, M., Tompkins, B. J., & Repp, A. B. (2025) · BMJ Open Quality · doi:10.1136/bmjoq-2025-003499 · Cited by 1
Jabbour, J., Issa, Z. A., Jaafar, T., Jaafari, S. A., Alaaedeen, L., Tabesh, A. A., Horanieh, R., Hammad, N. M., & Chakhtoura, M. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuaf297 · Cited by 1
Exploring Hypovitaminosis B12 in New Onset Type 2 Diabetes Mellitus and Prediabetes
Karanth, J. B., Maribashetti, K., & Karanth, G. J. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1359 · Cited by 1
Balamurugan, S., Mohan, R., Thomas, T. R. A., Florence, M. J. J., Mahendran, R., Manavalan, J., Balakrishna, P. R., Pasupathy, S., & Gopal, M. (2026) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2026.01.024 · Cited by 3
Islam, M. M., Hossain, S. B., Rahman, K. M., Sinthia, M. K., Chowdhury, A. B. M. A., & Khan, S. (2026) · HLRP Health Literacy Research and Practice · doi:10.3928/24748307-20260409-02 · Cited by 1
“Getting enough sleep is one of the most critical aspects of lifestyle therapy for diabetes management, according to new international guidelines (Garber et al., 2020).”
Alagbonsi, A. I., Kagina, A. P. N., Ingabire, D., Nayituriki, M., Alliance Tusifu, Abdulkadir, H. O., Olaniyi, A. O., Omeiza, N. A., & Gbadamosi, M. A. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s614442 · Cited by 3
“5,6 To monitor treatment efficacy, glycemic control has been assessed in various studies using HbA1c, self-monitoring of blood glucose, and continuous glucose monitoring (CGM).”
Greiner, B. H., Mercer, H., Raymond, C., Sonstein, L. K., & Hartwell, M. L. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108376 · Cited by 1
Estrategia terapéutica en el paciente diabético (III). Insulinoterapia
Ocaña, P. G., Cobos-Palacios, L., Muriel, C. C., & Jansen‐Chaparro, S. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.021 · Cited by 2
Shyshkan-Shyshova, К. О., Zinych, О. В., Кushnareva, N. M., Ковальчук, А., & Prybyla, О. В. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.8.2021.246792 · Cited by 3
Adel, S. M. H., Seyedian, M., & Nourizadeh, M. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1206_21 · Cited by 1
“Journal of Family Medicine and Primary Care 773 Volume 11 : Issue 2 : February 2022 suggested that increased HbA1c is a preventative factor in cardiac complications.[7]”
BackgroundO’Brien, H., & Travis, C. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.010 · Cited by 1
Correlation of lipid profile in diabetes patients
Khalid, M. R., Lakho, M. A., Zubair, M. F., Bhutto, A., Abbas, S., & Yousif, A. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns4.12168 · Cited by 1
Lifestyle and Nutrition Therapy
Ramchandani, S., Fox, C. M., Cann, S. B., Cronin, B., Canturk, A., Norman, C., & Sweeney, A. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_28 · Cited by 1
Baruah, M. P., Aneja, P., Pitale, S., Bhograj, A., Agrawala, R. K., Aggarwal, A., Mahadev, P. G., Madhavdas, D. C., Shah, S. C., John, M., et al. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1401_23 · Cited by 1
Baalmann, A. R., Norton, M. C., Gadbois‐Mincks, N. R., Ofei‐Dodoo, S., & Presnell, E. N. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70011 · Cited by 1
Koroleva, I. G., Sizova, Z. M., Ших, Е. В., Zakharova, V. L., Shindryaeva, N. N., & Melnik, M. V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-409 · Cited by 1
Zaghloul, N., Awaisu, A., Mahfouz, A., Ali, Z. O., Alyafei, S., & Elewa, H. F. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01828-5 · Cited by 1
Bhosle, D. S., Chandekar, B., & Shelke, S. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0925 · Cited by 1
Rentsch, T., Awad, M. H., Moorman, J. M., & Gothard, M. D. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001283 · Cited by 1
Addressing Nutritional Gaps: Simple Steps for the Primary Care Provider
Quan, Q. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0059 · Cited by 1
An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome
Lacy (2020) · The Journal of Family Practice · doi:10.12788/jfp.0060 · Cited by 1
Gokalani, R. A., Panchal, D., Saboo, B., Zinzuwadia, P., Patel, D., Chaudhury, R., Chavda, V., Phatak, S., Prasad, R., Dariya, S. S., et al. (2021) · Journal of Diabetology · doi:10.4103/jod.jod_81_20 · Cited by 1
Künstliche Intelligenz und maschinelles Lernen in der Diabetesforschung
Nguyen, P., Ohnmacht, A. J., Galhoz, A., Büttner, M., Theis, F. J., & Menden, M. P. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00817-w · Cited by 1
Kim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
Antoniou, S., Naka, K. Κ., Papadakis, M., Bechlioulis, A., Makriyiannis, D., Tsatsoulis, A. A., Michalis, L. K., & Tigas, S. K. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8120185 · Cited by 1
Krikorian, A., & Calimag, A. P. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_21 · Cited by 1
Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report
Alsifri, S. N., Elbadawi, H., Alsabaan, F., Almahfouz, A., Alyahya, K. A., Shesha, E., Esba, L. C. A., Alnais, M., Aldahash, R., Alharbi, T., et al. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.131002 · Cited by 1
Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA)
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_26 · Cited by 2
Arrieta, F., Pedro‐Botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G. F., Becerra, A., Navarro, J., Perez, J. C., Petrecca, R., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.01.005 · Cited by 3
Saedi, S., Amirzargar, M., Vahedinezhad, M., & Amirzargar, B. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0080 · Cited by 1
Part Two: Diabetes Part 2: A Review of Insulin Therapy in Older Patients
Phillippe, H. M., & Pogge, E. K. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.181 · Cited by 1
Diabetes: how to manage chronic kidney disease
Clements, J. N. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-10 · Cited by 1
Bae, J., Kim, Y.-E., Lee, M., Lee, Y., Lee, B., Soo, B., & Kang, E. S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.6.539 · Cited by 2
Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People
Sarbacker, G. B., Bzowyckyj, A. S., & Patel, R. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.251 · Cited by 1
Maximizing lifestyle changes to manage type 2 diabetes
McMullan (2022) · The Journal of Family Practice · doi:10.12788/jfp.0482 · Cited by 2
Utilizing type 2 diabetes medications outside glycemic parameters – where are we headed?
Malkani, N. P., & Aroda, V. R. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000787 · Cited by 2
Place of metformin in modern clinical guidelines for the treatment of type 2 diabetes mellitus
Моргунова, Т. Б., Glinkina, I. V., Дмитриевна, П. Е., Zorina, A. A., & Fadeev, V. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-211 · Cited by 2
Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide
Kahol, R., Jain, A., Sharma, N., & Mishra, S. K. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jun1950 · Cited by 1
Dedication to Alan J. Garber, MD, PhD, MACE
Samson, S. L., & Tangpricha, V. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.007 · Cited by 1
Self-citationWhy Are Cardiologists Not Prescribing the New Diabetes Medications?
Klein, L. W. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.040 · Cited by 1
Bailey, C. J., & Krentz, A. J. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch35 · Cited by 2
RESPONSE: The Imperative to Change the Delivery of Cardiometabolic Care
Kosiborod, M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.018
Paradigm shift in the management of DM & CVD —preventing the next CV event
Handelsman, Y., & Bloomgarden, Z. T. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13079
Self-citationEnchev, E., Esteve-Serra, M., Céspedes, L. M. R., Millan, R. B. S., Recasens-Sala, M., Sojo-Vega, L., Costa-Lima, E., Fernández‐Real, J. M., Ricart, W., & Fernández-Balsells, M. (2020) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000243
Planning, Constructing, and Operating a Clinic Gym
Nadolsky, K. Z., Nadolsky, S., & Freedhoff, Y. (2020) · Springer eBooks · doi:10.1007/978-3-030-48088-2_12
Introducing a novel therapy for type 2 diabetes to primary care
Brunton, S. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798686
Battise, D. M., & Olin, J. L. (2020) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000516
“(Hussein et al., 2020) However, one study found that longacting GLP1 RA (liraglutide, extended-release exenatide, semaglutide, and dulaglutide) had a greater impact than the short-acting GLP1 RA (lixisenatide), at an increase of six to 10 BPM compared with two to three BPM (Garg et al., 2019).”
BackgroundHot Topics in Primary Care 2020 Introduction
Brunton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0058
Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes
Wong, N. D., & Handelsman, Y. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_12 · Cited by 1
Self-citationThe New and Evolving Roles of Sodium Glucose Co-Transporter 2 Inhibitors
Irons, B. K. (2020) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2020.04.000585 · Cited by 1
“The CVOTs have also led to updates in clinical practice guidelines recommending the use of agents within this class that have demonstrated reduced cardiovascular outcomes in patients with T2D and cardiovascular disease [4,5].”
MethodReview of LDL-C Lowering with Focus on New and Emerging Agents
Brinton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0070
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician
Bakris (2020) · The Journal of Family Practice · doi:10.12788/jfp.0072
A New Era in Asthma Management: Assessment of Asthma Control
Murphy, M. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0061
Tan, X., Yang, L., Khunti, K., Zhang, R., Zhang, Y., Rajpathak, S. N., & Yu, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14466 · Cited by 1
Mikolajczak, J., & Herness, J. (2021) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001324
Williams, N. A., Brunton, S., & Scott, G. A. (2021) · Clinical Diabetes · doi:10.2337/cd21-0066 · Cited by 1
Metadata
- Authors
- Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., Garvey, W. T., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Perreault, L., Rosenblit, P. D., Samson, S., & Umpierrez, G. E.
- Affiliations
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California San Diego (US)
- Beth Israel Deaconess Medical Center (US)
- Kaiser Permanente (US)
- Ochsner Health System (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- University of Miami (US)
- Washington University in St. Louis (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Colorado Anschutz (US)
- University of California, Irvine (US)
- Emory University (US)
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 26
- Issue
- 1
- Pages
- 107-139
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3004838676
- Cited by
- 598
- References
- 300
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 80 · 2023: 104 · 2022: 146 · 2021: 125 · 2020: 81
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes management, glycemic control, cardiovascular risk, atherosclerotic cardiovascular disease, chronic kidney disease, diabetic ketoacidosis, obstructive sleep apnea, dyslipidemia, obesity, GLP-1 receptor agonists, SGLT2 inhibitors, insulin therapy, continuous glucose monitoring, self-monitoring of blood glucose
- MeSH terms
- Proprotein Convertase 9, Endocrinologists, Algorithms, Blood Glucose, Diabetes Mellitus, Type 2, Humans, United States, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.